Related Experiment Video
Updated: Apr 8, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
[Olaparib in ovarian cancer with BRCA mutation]
Éric Pujade-Lauraine1, Pierre Combe2
1Centre des cancers de la femme et recherche clinique, GH Paris Centre, site Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75181 Paris cedex 04, France.
Abstract:
With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes

